-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Reporter | Jin Miao
On April 14, the Zhejiang Pharmaceutical Equipment Procurement Center issued the "Notice on the Results of the Volume Procurement of Cefmetazole Injection Forms", which showed that in the first batch of volume procurement work in Zhejiang Province formally implemented on March 15th, Suzhou East The "Cefmetazole Sodium for Injection" (powder injection, specification 1.
0g) declared by Rui Pharmaceutical Co.
, Ltd.
was selected.
The company refused to fulfill the obligation of the selection, and has not completed the signing of the purchase and sales agreement and the resume distribution relationship, which affected the normal implementation of the selection results
.
The Zhejiang Pharmaceutical Equipment Purchasing Center decided to purchase the cefmetazole injection dosage form in quantity, and treat it as a non-selected product.
All medical and health institutions temporarily purchase according to the original method; each medical and health institution does not comply with the requirements due to Suzhou Dawnrays Pharmaceutical Co.
, Ltd.
If the performance of obligations causes losses or other civil rights are violated, rights can be protected in accordance with the law; drug procurement is related to the health of the masses.
In order to ensure normal medical order and clinical use of drugs, medical and health institutions should choose carefully, and try to avoid choosing breaches of contract, dishonesty, etc.
The company purchases products
.
Suzhou Dawnrays Pharmaceutical Co.
, Ltd.
is a subsidiary of Dawnrays Pharmaceuticals (Holdings) Co.
, Ltd.
The latter covers the entire industry chain of cephalosporin antibiotics APIs, intermediates, and powder injections.
It was listed on the main board of the Hong Kong Stock Exchange in 2003
.
Since the beginning of volume procurement at the end of 2018, the supply of selected products has been out of supply due to production capacity and price factors
.
In 2019, after Bristol-Myers Squibb’s Fosinopril Sodium Tablets followed up the "4+7" price in Hebei Province, due to insufficient supply, they could only be supplemented by the non-winning company Huahai Pharmaceutical
In 2020, the Yunnan Provincial Medical Insurance Bureau released 8 items that were abnormally supplied by selected enterprises in Yunnan for the centralized procurement of national drugs, involving Suzhou Dongrui, Xing'an Pharmaceutical, Changzhou Siyao, Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical, and Sinopharm Rongsheng Pharmaceutical , Hanhui Pharmaceutical, Guangzhou Baiyunshan Tianxin Pharmaceutical, Hunan Warner Pharmaceutical Factory's Entecavir, Atorvastatin Calcium, Amlodipine Besylate
.
During this cut-off, nearly one-third of the 25 varieties that were expanded by centralized procurement were cut-off
8:00 Jianwen previously reported that after the third batch of purchases by a certain southern hospital, it encountered a situation where sodium bicarbonate tablets and celecoxib tablets had not been delivered 5 months after the implementation
.
When the “floor price” of centralized procurement occurs frequently, and some winning bid prices are even difficult to cover costs, preventing companies from malicious bidding and reducing supply cuts caused by the difficulty of winning bid prices to cover costs have become key issues of concern to medical insurance departments in various regions
.
In August 2020, the National Medical Insurance Administration issued the "Guiding Opinions of the National Medical Security Administration on the Establishment of a Medical Price and Recruitment Credit Evaluation System" (abbreviated as the "Guiding Opinions"), which clearly proposes the establishment of a credit evaluation catalogue list to deal with improper price behaviors.
, Disrupting the order of centralized procurement, maliciously violating contractual agreements and other behaviors that are contrary to the city's credit, shall be included in the scope of medical prices and credit evaluation of recruitment and procurement
.
Since then, the "Guiding Opinions" have been implemented in various provinces and cities
.
Taking Guizhou Province as an example, in November 2020, the Guizhou Provincial Public Resources Trading Center announced that 11 pharmaceutical companies, 23 drugs, and 27 product specifications.